Galderma Pharmaceutical Expands in Quebec
Location Canada 2010
Galderma, which produces the skin care line Cetaphil, received more than $38 million from Investissement Quebec, the province's investment program, which targets product development projects by Quebec companies. The sum includes a non-refundable $3.8 million financial contribution that will help Galderma modernize and expand its drug manufacturing plant in Bai-d'Urfe.
"The government's support was a decisive factor in Galderma's decision to locate its center of excellence in Quebec," says Michel Sauvageau, manager of the Bai-d'Urfe plant. "In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art."
The funds will also allow Galderma to consolidate 240 positions and create 30 new, specialized jobs.
Supply Chain Bottlenecks Creating New “Logistical Hotspots”
2020 Top States for Doing Business Showcase Their Pro-Business Environments
2021 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
35th Annual Corporate Survey: Effects of Global Pandemic Reflected in Executives’ Site and Facility Plans
Auto Industry Is Betting on Sustainability
2021 Auto/Aero Site Guide
Latest Trends in the Industrial Real Estate Sector Here to Stay